Evvy raises $40M Series B
- Company
- Evvy
- Funding stage
- Series B
- Amount
- $40 million
- Date
- Location
- 🇺🇸 the US
- Sector
- Women's Health
- Investors
- Catalio Capital Management
What happened
Women's health company Evvy raised $40 million in a Series B round led by Catalio Capital Management. The company seeks to advance research using vaginal microbiome data.
Why it matters
A $40 million Series B led by healthcare specialist Catalio Capital Management brings institutional validation to microbiome-based diagnostic platforms. The capital backing expands thesis validation around data-driven women's healthcare solutions.
What to watch
Commercialization milestones for clinical diagnostic tools leveraging vaginal microbiome data sets.
VCBites Signal
Why this score: A $40 million Series B led by a dedicated life sciences investor like Catalio represents a solid, high-conviction growth round in healthtech.
VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.
Who should care?
- Healthtech Founders
- Healthcare Investors
- Biotech
Source
This is an original short summary. Read the full reporting at the original source.
Read the original story on TechCrunchShare the signal
VC Bites
Evvy raises $40M Series B
VCBITES SIGNAL: 53 / 100
Why it matters
A $40 million Series B led by healthcare specialist Catalio Capital Management brings institutional validation to microbiome-based diagnostic platforms. The capital backing expands thesis validation around data-driven women's healthcare solutions.
VC Bites · Venture capital signals, explained.
The post text is copied to your clipboard so you can paste it alongside the link.